Author: Mougenot Philippe
Publisher: Springer Publishing Company
ISSN: 0031-6970
Source: European Journal of Clinical Pharmacology, Vol.64, Iss.6, 2008-06, pp. : 635-639
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Agalsidase Beta: A Review of its Use in the Management of Fabry Disease
By Keating Gillian M. Simpson Dene
Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. :
Treatment of Fabry Disease: Current and Emerging Strategies
Current Pharmaceutical Biotechnology, Vol. 12, Iss. 6, 2011-06 ,pp. :
-Galactosidase appears to decrease cardiac mass and correct the metabolic defect of Fabry's disease
Inpharma, Vol. 1, Iss. 1292, 2001-01 ,pp. :